LifeMD Q1 Revenue Exceeds $50.2 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Backs FY26 adjusted EBITDA $12M-$17M. "The first quarter played out largely as we expected: strong subscriber momentum, following a planned step-up in patient acquisition spend, and the early benefits of platform efficiency beginning to show in our gross margin," said Atul Kavthekar, Chief Financial Officer of LifeMD. "Revenue for the first quarter was $50.2 million, exceeding our guidance range of $48 million to $49 million, with nearly all revenue derived from recurring subscriptions. The number of active subscribers increased approximately 26% year-over-year to over 365,000 at quarter end, with over 42,000 net adds in Q1, the largest quarterly net addition in our history. We exited the quarter with $34.5 million in cash, no debt, and a $30 million undrawn revolving credit facility that we put in place at the start of the year. Our balance sheet remains a strategic asset, providing ample flexibility to fund our expanding growth initiatives."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFMD
Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.910
Low
6.00
Averages
9.67
High
15.00
Current: 4.910
Low
6.00
Averages
9.67
High
15.00
About LFMD
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx Shares Surge 11.5% on Positive Analysis and Earnings Outlook
- Significant Price Surge: CareDx shares rallied 11.5% in the last trading session to close at $26.18, with trading volume notably higher than typical, reflecting strong investor confidence in the company's outlook.
- Support from Analysis: The stock's rise is closely tied to the publication of the KOAR analysis in the Journal of the American Society of Nephrology, which supports the role of AlloSure Kidney as a noninvasive tool for risk stratification and clinical decision-making, boosting investor optimism.
- Strong Earnings Expectations: CareDx is expected to report quarterly earnings of $0.22 per share, representing a 120% year-over-year increase, with revenues projected at $114.35 million, up 31.9% from the previous year, indicating robust growth potential in the medical services sector.
- Increased Market Attention: Although the consensus EPS estimate has remained unchanged over the past 30 days, the stock's continued upward movement suggests heightened market interest in CareDx's future performance, prompting investors to monitor its trajectory for sustained strength.
See More
LifeMD Appoints Umesh Sripad as CTO to Drive Technology Strategy
- Executive Appointment: LifeMD announced the appointment of Umesh Sripad as Chief Technology Officer, effective immediately, with Sripad tasked to lead the company's technology strategy, platform transformation, AI enablement, and cybersecurity initiatives to support its rapid expansion goals.
- Stock Incentive Plan: The company will grant Sripad 150,000 restricted stock units, with 75,000 vesting based on his continued service and an additional 75,000 tied to the achievement of performance targets, aiming to attract and retain top executive talent.
- Extensive Industry Experience: Prior to joining LifeMD, Sripad served as Chief Digital and Technology Officer at PetMeds, overseeing digital commerce and technology transformation, and held executive roles at PureRED, Bed Bath & Beyond, and IKEA USA, showcasing his strong background in digital transformation.
- Financial Outlook: LifeMD reaffirmed its 2026 revenue guidance of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million, targeting over $250 million in run-rate revenue by Q4, reflecting the company's confidence in future growth.
See More
LifeMD Reports Strong Q1 2026 Earnings with Record Subscriber Growth
- Significant Revenue Growth: LifeMD reported revenue of $50.2 million in Q1 2026, exceeding guidance, while adding over 42,000 net telehealth subscribers, marking the largest quarterly increase in its history, indicating strong market performance and sustained customer demand.
- Surge in Weight Management Patients: The number of sign-ups in weight management increased approximately 120% sequentially from Q4, reaching nearly 100,000 patients, demonstrating rapid expansion in this segment and enhanced customer attraction.
- Gross Margin Improvement: The gross margin for the quarter expanded by approximately 420 basis points to 88%, with gross profit at $44.2 million, reflecting successful operational efficiency and cost control, thereby strengthening the foundation for future profitability.
- Optimistic Future Outlook: Management reaffirmed full-year revenue guidance of $220 million to $230 million, with expected adjusted EBITDA exceeding $25 million by Q4, showcasing confidence in future growth and clarity in strategic planning.
See More
LifeMD Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: LifeMD reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.03, indicating potential improvements in profitability.
- Revenue Performance: The company generated $50.2 million in revenue for Q1, a 23.6% year-over-year decline, yet it surpassed market expectations by $1.32 million, demonstrating resilience in a challenging market.
- Gross Margin Expansion: Gross profit rose by 3% to $44.2 million, with gross margin expanding from 84% to 88% year-over-year, primarily due to an optimized product mix, showcasing effective cost management and pricing strategies.
- Increased Marketing Spend: Selling and marketing expenses surged by 34% to $29.9 million, reflecting strategic investments in front-loaded patient acquisition aimed at driving accelerated growth in the upcoming quarters.
See More
LifeMD's Business Doubles Following Wegovy Pill Launch
- Significant Business Growth: Following the launch of the Wegovy pill, LifeMD experienced a surge in daily new patients from 300-400 to 600-1,000, indicating strong market demand for oral GLP-1 medications and solidifying its position in telehealth.
- Intensified Market Competition: The successful introduction of Novo Nordisk's Wegovy pill in the U.S. has forced investors to reassess the market potential for oral GLP-1 drugs, particularly after Eli Lilly's Foundayo launch, which has shown a more modest market response, highlighting Novo's competitive edge.
- Increased Patient Acceptance: The lower price and efficacy of the Wegovy pill have led to a growing preference for oral medications over injections, with a notable increase in male patients, which not only expands the GLP-1 market reach but also potentially brings in a more diverse patient demographic.
- Uncertain Future Outlook: Despite the strong performance of Novo's Wegovy pill, analysts remain pessimistic about future sales and profit forecasts, expecting a decline of 5% to 13% by 2026, which could impact investor confidence and pose challenges for the company's long-term growth.
See More
LifeMD Launches Foundayo to Enhance Obesity Management Services
- New Drug Launch: LifeMD has officially launched Foundayo (orforglipron), an oral medication developed by Eli Lilly, providing a once-daily treatment option for adults with obesity or overweight, marking a significant expansion in the company's obesity management offerings.
- Pricing and Insurance: The self-pay starting price for Foundayo is $149 per month, while eligible patients with commercial insurance can pay as little as $25 per month through a Lilly savings card, with Medicare coverage expected to begin in July 2026, significantly reducing the financial burden on patients.
- Integrated Services: By integrating with LillyDirect, LifeMD can offer direct prescription fulfillment and shipping to patients, ensuring quick and convenient access to treatment, which enhances service efficiency and patient satisfaction.
- Market Positioning: The launch of Foundayo not only expands LifeMD's portfolio of GLP-1 therapies but also reinforces its leadership position in clinically guided obesity management, demonstrating the company's commitment to providing high-quality, affordable healthcare services.
See More
CareDx Shares Surge 11.5% on Positive Analysis and Earnings Outlook
- Significant Price Surge: CareDx shares rallied 11.5% in the last trading session to close at $26.18, with trading volume notably higher than typical, reflecting strong investor confidence in the company's outlook.
- Support from Analysis: The stock's rise is closely tied to the publication of the KOAR analysis in the Journal of the American Society of Nephrology, which supports the role of AlloSure Kidney as a noninvasive tool for risk stratification and clinical decision-making, boosting investor optimism.
- Strong Earnings Expectations: CareDx is expected to report quarterly earnings of $0.22 per share, representing a 120% year-over-year increase, with revenues projected at $114.35 million, up 31.9% from the previous year, indicating robust growth potential in the medical services sector.
- Increased Market Attention: Although the consensus EPS estimate has remained unchanged over the past 30 days, the stock's continued upward movement suggests heightened market interest in CareDx's future performance, prompting investors to monitor its trajectory for sustained strength.
See More
LifeMD Appoints Umesh Sripad as CTO to Drive Technology Strategy
- Executive Appointment: LifeMD announced the appointment of Umesh Sripad as Chief Technology Officer, effective immediately, with Sripad tasked to lead the company's technology strategy, platform transformation, AI enablement, and cybersecurity initiatives to support its rapid expansion goals.
- Stock Incentive Plan: The company will grant Sripad 150,000 restricted stock units, with 75,000 vesting based on his continued service and an additional 75,000 tied to the achievement of performance targets, aiming to attract and retain top executive talent.
- Extensive Industry Experience: Prior to joining LifeMD, Sripad served as Chief Digital and Technology Officer at PetMeds, overseeing digital commerce and technology transformation, and held executive roles at PureRED, Bed Bath & Beyond, and IKEA USA, showcasing his strong background in digital transformation.
- Financial Outlook: LifeMD reaffirmed its 2026 revenue guidance of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million, targeting over $250 million in run-rate revenue by Q4, reflecting the company's confidence in future growth.
See More
LifeMD Reports Strong Q1 2026 Earnings with Record Subscriber Growth
- Significant Revenue Growth: LifeMD reported revenue of $50.2 million in Q1 2026, exceeding guidance, while adding over 42,000 net telehealth subscribers, marking the largest quarterly increase in its history, indicating strong market performance and sustained customer demand.
- Surge in Weight Management Patients: The number of sign-ups in weight management increased approximately 120% sequentially from Q4, reaching nearly 100,000 patients, demonstrating rapid expansion in this segment and enhanced customer attraction.
- Gross Margin Improvement: The gross margin for the quarter expanded by approximately 420 basis points to 88%, with gross profit at $44.2 million, reflecting successful operational efficiency and cost control, thereby strengthening the foundation for future profitability.
- Optimistic Future Outlook: Management reaffirmed full-year revenue guidance of $220 million to $230 million, with expected adjusted EBITDA exceeding $25 million by Q4, showcasing confidence in future growth and clarity in strategic planning.
See More
LifeMD Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: LifeMD reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.03, indicating potential improvements in profitability.
- Revenue Performance: The company generated $50.2 million in revenue for Q1, a 23.6% year-over-year decline, yet it surpassed market expectations by $1.32 million, demonstrating resilience in a challenging market.
- Gross Margin Expansion: Gross profit rose by 3% to $44.2 million, with gross margin expanding from 84% to 88% year-over-year, primarily due to an optimized product mix, showcasing effective cost management and pricing strategies.
- Increased Marketing Spend: Selling and marketing expenses surged by 34% to $29.9 million, reflecting strategic investments in front-loaded patient acquisition aimed at driving accelerated growth in the upcoming quarters.
See More
LifeMD's Business Doubles Following Wegovy Pill Launch
- Significant Business Growth: Following the launch of the Wegovy pill, LifeMD experienced a surge in daily new patients from 300-400 to 600-1,000, indicating strong market demand for oral GLP-1 medications and solidifying its position in telehealth.
- Intensified Market Competition: The successful introduction of Novo Nordisk's Wegovy pill in the U.S. has forced investors to reassess the market potential for oral GLP-1 drugs, particularly after Eli Lilly's Foundayo launch, which has shown a more modest market response, highlighting Novo's competitive edge.
- Increased Patient Acceptance: The lower price and efficacy of the Wegovy pill have led to a growing preference for oral medications over injections, with a notable increase in male patients, which not only expands the GLP-1 market reach but also potentially brings in a more diverse patient demographic.
- Uncertain Future Outlook: Despite the strong performance of Novo's Wegovy pill, analysts remain pessimistic about future sales and profit forecasts, expecting a decline of 5% to 13% by 2026, which could impact investor confidence and pose challenges for the company's long-term growth.
See More
LifeMD Launches Foundayo to Enhance Obesity Management Services
- New Drug Launch: LifeMD has officially launched Foundayo (orforglipron), an oral medication developed by Eli Lilly, providing a once-daily treatment option for adults with obesity or overweight, marking a significant expansion in the company's obesity management offerings.
- Pricing and Insurance: The self-pay starting price for Foundayo is $149 per month, while eligible patients with commercial insurance can pay as little as $25 per month through a Lilly savings card, with Medicare coverage expected to begin in July 2026, significantly reducing the financial burden on patients.
- Integrated Services: By integrating with LillyDirect, LifeMD can offer direct prescription fulfillment and shipping to patients, ensuring quick and convenient access to treatment, which enhances service efficiency and patient satisfaction.
- Market Positioning: The launch of Foundayo not only expands LifeMD's portfolio of GLP-1 therapies but also reinforces its leadership position in clinically guided obesity management, demonstrating the company's commitment to providing high-quality, affordable healthcare services.
See More
